SCHEMBL3488948

SCHEMBL3488948

CN(C)C(=O)c1cc(-c2cnc3c(c2)c(Cc2cccc(Cl)c2)nn3COC(=O)C(C)(C)C)ccc1NC(=O)N1CCOCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
PRMT6 Q96LA8 2/20 0.34
AOC3 Q16853 2/20 0.34
CTSS P25774 1/20 0.33
NTRK1 P04629 1/20 0.33
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
MAPK1 P28482 1/20 0.32
DYRK1B Q9Y463 1/20 0.32
PDK1 Q15118 1/20 0.32
FKBP1A P62942 1/20 0.32
NPC1 O15118 1/20 0.31
PKM P14618 1/20 0.31
RAB9A P51151 1/20 0.31
AVPR1B P47901 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13600201 0.87 ALDH1A1 (0.39) KDM4EALDH1A1HPGDPRMT6AOC3
SCHEMBL12344668 0.84 KDM4E (0.36) KDM4EALDH1A1HPGDPRMT6AOC3
SCHEMBL3489336 0.83 MAP4K1 (0.43)
SCHEMBL12344670 0.81 NTRK1 (0.40) KDM4EALDH1A1HPGDPRMT6AOC3
SCHEMBL3489894 0.80 KDM4E (0.34) KDM4EALDH1A1HPGDAOC3CTSS
SCHEMBL3566219 0.75 KDM4E (0.33) KDM4EALDH1A1HPGDPRMT6NPC1
SCHEMBL12344667 0.74 CLK2 (0.41) PRMT6AOC3NTRK1
SCHEMBL3489573 0.71 MAP4K1 (0.43)
SCHEMBL12344640 0.70 HDAC3 (0.39) PRMT6NTRK1MAPK1
SCHEMBL13342408 0.67 HSD17B10 (0.37) KDM4EALDH1A1HPGDPRMT6MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268994-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-09-18 US disclosed
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators SGX PHARMACEUTICALS, INC. 2010-02-11 US disclosed
EP-2134179-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
WO-2008124850-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, TTK, MAP3K19 KDM4E 832/4885ALDH1A1 4383/4885HPGD 2710/4885
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators MAP3K20, TTK, MAP3K19 KDM4E 832/4885ALDH1A1 4383/4885HPGD 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.